These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14515113)

  • 21. Gender disparities in lipid management: the presence of disparities depends on the quality measure.
    Kim C; Kerr EA; Bernstein SJ; Krein SL
    Am J Manag Care; 2006 Mar; 12(3):133-6. PubMed ID: 16524345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achieving target cholesterol levels in diabetic patients: potency of the statin or potency of the physician?
    Shani M; Dresner J; Vinker S
    Isr Med Assoc J; 2008 May; 10(5):354-7. PubMed ID: 18605358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A national study on lipid management.
    Jotkowitz AB; Novack V; Rabinowitz G; Segal AR; Weitzman R; Porath A
    Eur J Intern Med; 2008 Jul; 19(5):356-61. PubMed ID: 18549939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins.
    Castro Cabezas M; de Vries JH; Van Oostrom AJ; Iestra J; van Staveren WA
    J Am Diet Assoc; 2006 Oct; 106(10):1564-9. PubMed ID: 17000189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
    Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
    Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
    Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A
    J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.
    Mann D; Reynolds K; Smith D; Muntner P
    Ann Pharmacother; 2008 Sep; 42(9):1208-15. PubMed ID: 18648016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
    Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival.
    Leeper NJ; Ardehali R; deGoma EM; Heidenreich PA
    Circulation; 2007 Aug; 116(6):613-8. PubMed ID: 17664373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
    Wiviott SD; Mohanavelu S; Raichlen JS; Cain VA; Nissen SE; Libby P
    Am J Cardiol; 2009 Jul; 104(1):29-35. PubMed ID: 19576317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
    Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.